Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Kadowaki, Takashi ^a   Morishita, Asahiro ^a   Niki, Toshiro ^a   Hara, Junko ^b   Sato, Miwa ^b   Tani, Joji ^a   Miyoshi, Hisaaki ^a   Yoneyama, Hirohito ^a   Masaki, Tsutomu ^a   Hattori, Toshio ^c   Matsukawa, Akihiro ^b   Hirashima, Mitsuomi ^a,d  

^a KAGAWA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GALECTIN; GLYCOPROTEIN P 15095; HAVCR2 PROTEIN, MOUSE; LGALS9 PROTEIN, MOUSE; VIRUS RECEPTOR;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BLOOD; CYTOLOGY; DENDRITIC CELL; DISEASE MODEL; IMMUNOLOGY; MACROPHAGE; MALE; METABOLISM; NATURAL KILLER T CELL; NUDE MOUSE; SEPSIS; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD11C; APOPTOSIS; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GALECTINS; MACROPHAGES; MALE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; RECEPTORS, VIRUS; SEPSIS; SPLEEN;

EID: 84889862349     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13147     Document Type: Article

References (50)

1. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664. 10.1038/330662a0, 3317066.
2. McNamara MJ, Norton JA, Nauta RJ, Alexander HR. Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J Surgical Res 1993, 54:316-321.
3. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251. 10.1126/science.285.5425.248, 10398600.
4. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101:296-301. 10.1073/pnas.2434651100, 314179, 14695889.
5. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006, 203:1637-1642. 10.1084/jem.20052203, 2118346, 16818669.
6. Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Ebina M, Yamada S, Hashimoto S, Fukata S, Abraham E, Maruyama I, Kitajima M, Ishizaka A. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30:1755-1762. 10.1007/s00268-005-0369-2, 16850155.
7. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 2009, 106:6303-6308. 10.1073/pnas.0809422106, 2669369, 19332785.
8. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15:R70. 10.1186/cc10059, 3222003, 21349174.
9. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15:R99. 10.1186/cc10112, 3219369, 21418617.
10. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukocyte Biol 2010, 88:233-240. 10.1189/jlb.0110037, 20483923.
11. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14:R220. 10.1186/cc9354, 3220038, 21118528.
12. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008, 181:6707-6710.
13. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997, 272:6078-6086. 10.1074/jbc.272.9.6078, 9038233.
14. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest 1997, 99:2452-2461. 10.1172/JCI119429, 508086, 9153289.
15. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998, 273:16976-16984. 10.1074/jbc.273.27.16976, 9642261.
16. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252. 10.1038/ni1271, 16286920.
17. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, Nishi N, Yamauchi A, Katoh S, Matsukawa A, Kuchroo V, Hirashima M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008, 127:78-88. 10.1016/j.clim.2008.01.006, 18282810.
18. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, Yamauchi A, Hirashima M. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol 2012, 143:51-58. 10.1016/j.clim.2012.01.004, 22341088.
19. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, Kojima K, Nagahara K, Miyake M, Yamauchi A, Kohrogi H, Hirashima M. Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol 2010, 40:548-558. 10.1002/eji.200939886, 19902429.
20. Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A, Hirashima M. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol 2009, 130:322-330. 10.1016/j.clim.2008.09.014, 18974023.
21. Kojima K, Arikawa T, Saita N, Goto E, Tsumura S, Tanaka R, Masunaga A, Niki T, Oomizu S, Hirashima M, Kohrogi H. Galectin-9 attenuates acute lung injury by expanding CD14- plasmacytoid dendritic cell-like macrophages. Am J Respir Crit Care Med 2011, 184:328-339. 10.1164/rccm.201010-1566OC, 21562126.
22. Kadowaki T, Arikawa T, Shinonaga R, Oomizu S, Inagawa H, Soma G, Niki T, Hirashima M. Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages. Clin Immunol 2012, 142:296-307. 10.1016/j.clim.2011.11.006, 22177847.
23. Kadowaki T, Shimada M, Inagawa H, Kohchi C, Hirashima M, Soma G. Reconsideration of macrophage and dendritic cell classification. Anticancer Res 2012, 32:2257-2261.
24. Tsuboi Y, Abe H, Nakagawa R, Oomizu S, Watanabe K, Nishi N, Nakamura T, Yamauchi A, Hirashima M. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin Immunol 2007, 124:221-233. 10.1016/j.clim.2007.04.015, 17560833.
25. Watanabe H, Kubo M, Numata K, Takagi K, Mizuta H, Okada S, Ito T, Matsukawa A. Overexpression of suppressor of cytokine signaling-5 in T cells augments innate immunity during septic peritonitis. J Immunol 2006, 177:8650-8657.
26. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005, 579:2058-2064. 10.1016/j.febslet.2005.02.054, 15811318.
27. Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009, 32:348-357. 10.1097/SHK.0b013e3181a551bd, 2860725, 19333143.
28. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J Immunol 2002, 169:384-392.
29. Hiraki S, Ono S, Kinoshita M, Tsujimoto H, Takahata R, Miyazaki H, Saitoh D, Seki S, Hase K. Neutralization of IL-10 restores the downregulation of IL-18 receptor on natural killer cells and interferon-gamma production in septic mice, thus leading to an improved survival. Shock 2012, 37:177-182. 10.1097/SHK.0b013e31823f18ad, 22089189.
30. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008, 226:57-79. 10.1111/j.1600-065X.2008.00699.x, 19161416.
31. Kondo T, Takata H, Matsuki F, Takiguchi M. Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 2009, 182:1794-1798. 10.4049/jimmunol.0801347, 19201830.
32. Hamada H, Garcia-Hernandez Mde L, Reome JB, Misra SK, Strutt TM, McKinstry KK, Cooper AM, Swain SL, Dutton RW. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 2009, 182:3469-3481. 10.4049/jimmunol.0801814, 2667713, 19265125.
33. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008, 180:5167-5171. 2442579, 18390697.
34. Lee KA, Kang MH, Lee YS, Kim YJ, Kim DH, Ko HJ, Kang CY. A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity. Cell Immunol 2008, 251:50-55. 10.1016/j.cellimm.2008.03.004, 18423430.
35. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006, 177:4662-4669.
36. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol 2008, 20:353-357. 10.1016/j.coi.2008.03.006, 2601685, 18439808.
37. Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ferrara JL, Ward PA. Adverse functions of IL-17A in experimental sepsis. FASEB J 2008, 22:2198-2205. 10.1096/fj.07-105221, 18299333.
38. Freitas A, Alves-Filho JC, Victoni T, Secher T, Lemos HP, Sonego F, Cunha FQ, Ryffel B. IL-17 receptor signaling is required to control polymicrobial sepsis. J Immunol 2009, 182:7846-7854. 10.4049/jimmunol.0803039, 19494309.
39. Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, Krause H, Kunzendorf U. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997, 3:1124-1128. 10.1038/nm1097-1124, 9334724.
40. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, Osborne DF, Clark AT, Coopersmith CM, McDunn JE, Hotchkiss RS. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010, 184:1401-1409. 10.4049/jimmunol.0902307, 2937828, 20026737.
41. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, Nagahata S, Hirabayashi J, Kuchroo VK, Yamauchi A, Hirashima M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008, 181:7660-7669.
42. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143. 10.1126/science.1148536, 18006747.
43. Leung B, Harris HW. NKT cells: the culprits of sepsis?. J Surgical Res 2011, 167:87-95.
44. Sireci G, La Manna MP, Di Sano C, Di Liberto D, Porcelli SA, Kronenberg M, Dieli F, Salerno A. Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock. J Leukocyte Biol 2007, 81:607-622.
45. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237. 10.1038/nri1309, 15039760.
46. Tulley JM, Palmer JL, Gamelli RL, Faunce DE. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide. Shock 2008, 29:269-277. 10.1097/shk.0b013e31811ff60c, 17693934.
47. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524. 10.1038/nm0503-517, 12724763.
48. Ding Y, Chung CS, Newton S, Chen Y, Carlton S, Albina JE, Ayala A. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 2004, 22:137-144. 10.1097/01.shk.0000131194.80038.3f, 2253681, 15257086.
49. Flohe SB, Agrawal H, Schmitz D, Gertz M, Flohe S, Schade FU. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukocyte Biol 2006, 79:473-481.
50. Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susarla S, Ulloa L, Yang H, Fan S, Goyert SM, Wang P, Tracey KJ, Sama AE, Wang H. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukocyte Biol 2004, 76:994-1001. 10.1189/jlb.0404242, 15331624.